Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pathogenesis of Itch in Response to Apremilast in Psoriasis
NCT03146247Phase 4Withdrawn
- Start
- Oct 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apremilast in plaque psoriasis. Primary endpoint: Immunoreactive nerve fibers density at 16 weeks. Planned start Oct 2017; status: withdrawn.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03146247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146247.